108 related articles for article (PubMed ID: 20669312)
1. Safety and tolerability of high-dosage coenzyme Q10 in Huntington's disease and healthy subjects.
; Hyson HC; Kieburtz K; Shoulson I; McDermott M; Ravina B; de Blieck EA; Cudkowicz ME; Ferrante RJ; Como P; Frank S; Zimmerman C; Cudkowicz ME; Ferrante K; Newhall K; Jennings D; Kelsey T; Walker F; Hunt V; Daigneault S; Goldstein M; Weber J; Watts A; Beal MF; Browne SE; Metakis LJ
Mov Disord; 2010 Sep; 25(12):1924-8. PubMed ID: 20669312
[TBL] [Abstract][Full Text] [Related]
2. Assessment of coenzyme Q10 tolerability in Huntington's disease.
Feigin A; Kieburtz K; Como P; Hickey C; Claude K; Abwender D; Zimmerman C; Steinberg K; Shoulson I
Mov Disord; 1996 May; 11(3):321-3. PubMed ID: 8723151
[TBL] [Abstract][Full Text] [Related]
3. Pilot trial of high dosages of coenzyme Q10 in patients with Parkinson's disease.
Shults CW; Flint Beal M; Song D; Fontaine D
Exp Neurol; 2004 Aug; 188(2):491-4. PubMed ID: 15246848
[TBL] [Abstract][Full Text] [Related]
4. Randomized, double-blind, placebo-controlled trial on symptomatic effects of coenzyme Q(10) in Parkinson disease.
Storch A; Jost WH; Vieregge P; Spiegel J; Greulich W; Durner J; Müller T; Kupsch A; Henningsen H; Oertel WH; Fuchs G; Kuhn W; Niklowitz P; Koch R; Herting B; Reichmann H;
Arch Neurol; 2007 Jul; 64(7):938-44. PubMed ID: 17502459
[TBL] [Abstract][Full Text] [Related]
5. Safety assessment of coenzyme Q10 (Kaneka Q10) in healthy subjects: a double-blind, randomized, placebo-controlled trial.
Ikematsu H; Nakamura K; Harashima S; Fujii K; Fukutomi N
Regul Toxicol Pharmacol; 2006 Apr; 44(3):212-8. PubMed ID: 16431002
[TBL] [Abstract][Full Text] [Related]
6. Duloxetine for the treatment of major depressive disorder: safety and tolerability associated with dose escalation.
Wohlreich MM; Mallinckrodt CH; Prakash A; Watkin JG; Carter WP
Depress Anxiety; 2007; 24(1):41-52. PubMed ID: 16845641
[TBL] [Abstract][Full Text] [Related]
7. A controlled trial of remacemide hydrochloride in Huntington's disease.
Kieburtz K; Feigin A; McDermott M; Como P; Abwender D; Zimmerman C; Hickey C; Orme C; Claude K; Sotack J; Greenamyre JT; Dunn C; Shoulson I
Mov Disord; 1996 May; 11(3):273-7. PubMed ID: 8723144
[TBL] [Abstract][Full Text] [Related]
8. Tolerance of high-dose (3,000 mg/day) coenzyme Q10 in ALS.
Ferrante KL; Shefner J; Zhang H; Betensky R; O'Brien M; Yu H; Fantasia M; Taft J; Beal MF; Traynor B; Newhall K; Donofrio P; Caress J; Ashburn C; Freiberg B; O'Neill C; Paladenech C; Walker T; Pestronk A; Abrams B; Florence J; Renna R; Schierbecker J; Malkus B; Cudkowicz M
Neurology; 2005 Dec; 65(11):1834-6. PubMed ID: 16344537
[TBL] [Abstract][Full Text] [Related]
9. Effect of coenzyme Q10 and vitamin E on brain energy metabolism in the animal model of Huntington's disease.
Kasparová S; Sumbalová Z; Bystrický P; Kucharská J; Liptaj T; Mlynárik V; Gvozdjáková A
Neurochem Int; 2006 Jan; 48(2):93-9. PubMed ID: 16290265
[TBL] [Abstract][Full Text] [Related]
10. CYTE-I-HD: phase I dose finding and tolerability study of cysteamine (Cystagon) in Huntington's disease.
Dubinsky R; Gray C
Mov Disord; 2006 Apr; 21(4):530-3. PubMed ID: 16258942
[TBL] [Abstract][Full Text] [Related]
11. Open-label pilot study of levetiracetam (Keppra) for the treatment of chorea in Huntington's disease.
Zesiewicz TA; Sullivan KL; Hauser RA; Sanchez-Ramos J
Mov Disord; 2006 Nov; 21(11):1998-2001. PubMed ID: 16941461
[TBL] [Abstract][Full Text] [Related]
12. A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington's disease.
Huntington Study Group
Neurology; 2001 Aug; 57(3):397-404. PubMed ID: 11502903
[TBL] [Abstract][Full Text] [Related]
13. Energy metabolism defects in Huntington's disease and effects of coenzyme Q10.
Koroshetz WJ; Jenkins BG; Rosen BR; Beal MF
Ann Neurol; 1997 Feb; 41(2):160-5. PubMed ID: 9029064
[TBL] [Abstract][Full Text] [Related]
14. Dose ranging and efficacy study of high-dose coenzyme Q10 formulations in Huntington's disease mice.
Smith KM; Matson S; Matson WR; Cormier K; Del Signore SJ; Hagerty SW; Stack EC; Ryu H; Ferrante RJ
Biochim Biophys Acta; 2006 Jun; 1762(6):616-26. PubMed ID: 16647250
[TBL] [Abstract][Full Text] [Related]
15. A randomized, double-blind, placebo-controlled trial of pridopidine in Huntington's disease.
Huntington Study Group HART Investigators
Mov Disord; 2013 Sep; 28(10):1407-15. PubMed ID: 23450660
[TBL] [Abstract][Full Text] [Related]
16. Long-term Safety and Tolerability of Colesevelam HCl in Subjects with Type 2 Diabetes.
Goldfine AB; Fonseca VA; Jones MR; Wang AC; Ford DM; Truitt KE
Horm Metab Res; 2010 Jan; 42(1):23-30. PubMed ID: 19862667
[TBL] [Abstract][Full Text] [Related]
17. Coenzyme Q10 serum levels in Huntington's disease.
Andrich J; Saft C; Gerlach M; Schneider B; Arz A; Kuhn W; Müller T
J Neural Transm Suppl; 2004; (68):111-6. PubMed ID: 15354396
[TBL] [Abstract][Full Text] [Related]
18. A 26-week, prospective, open-label, uncontrolled, multicenter study to evaluate the effect of an escalating-dose regimen of trandolapril on change in blood pressure in treatment-naive and concurrently treated adult hypertensive subjects (TRAIL).
Tytus RH; Burgess ED; Assouline L; Vanjaka A
Clin Ther; 2007 Feb; 29(2):305-15. PubMed ID: 17472822
[TBL] [Abstract][Full Text] [Related]
19. Risk assessment for coenzyme Q10 (Ubiquinone).
Hathcock JN; Shao A
Regul Toxicol Pharmacol; 2006 Aug; 45(3):282-8. PubMed ID: 16814438
[TBL] [Abstract][Full Text] [Related]
20. Cetilistat (ATL-962), a novel lipase inhibitor: a 12-week randomized, placebo-controlled study of weight reduction in obese patients.
Kopelman P; Bryson A; Hickling R; Rissanen A; Rossner S; Toubro S; Valensi P
Int J Obes (Lond); 2007 Mar; 31(3):494-9. PubMed ID: 16953261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
